Prevention of invasive Candida infections in preterm infants: the time is now

References

• Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995–2004. Pediatrics117, 1680–1687 (2006).
   PubMed Web of Science ®Google Scholar
• Cotten CM, McDonald S, Stoll B et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics118, 717–722 (2006).
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen NI, Adams-Chapman I et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA292, 2357–2365 (2004).
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Stoll BJ, Fanaroff AA et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics117, 84–92 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman D, Boyle R, Hazen KC et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med.345, 1660–1666 (2001).
   PubMed Web of Science ®Google Scholar
• Kicklighter SD, Springer SC, Cox T, Hulsey TC, Turner RB. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics107, 293–298 (2001).
   PubMed Web of Science ®Google Scholar
• Kaufman D, Boyle R, Hazen KC et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J. Pediatr.147, 172–179 (2005).
   PubMed Web of Science ®Google Scholar
• Healy CM, Baker CJ, Zaccaria E, Campbell JR. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr.147, 166–171 (2005).
   PubMed Web of Science ®Google Scholar
• Bertini G, Perugi S, Dani C et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J. Pediatr.147, 162–165 (2005).
   PubMed Web of Science ®Google Scholar
• Manzoni P, Stolfi I, Pugni L et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med.356, 2483–2495 (2007).
   PubMed Web of Science ®Google Scholar
• Manzoni P, Arisio R, Mostert M et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics117, e22–e32 (2006).
   PubMed Web of Science ®Google Scholar
• Uko S, Soghier LM, Vega M et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics117, 1243–1252 (2006).
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Mudduluru M, Nakhla TA et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J. Perinatol.26, 550–555 (2006).
   PubMed Web of Science ®Google Scholar
• Healy CM, Campbell JR, Zaccaria E, Baker CJ. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics121, 703–710 (2008).
   PubMed Web of Science ®Google Scholar
• Weitkamp JH, Ozdas A, Lafleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J. Perinatol.28(6), 405–411 (2008).
   PubMed Web of Science ®Google Scholar
• Smith PB, Morgan J, Benjamin JD et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr. Infect. Dis. J.26, 197–200 (2007).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Localio R, Walsh TJ, Feudtner C. Outcomes attributable to neonatal candidiasis. Clin. Infect. Dis.44, 1187–1193 (2007).
   PubMed Web of Science ®Google Scholar
• Procianoy RS, Eneas MV, Silveira RC. Empiric guidelines for treatment of Candida infection in high-risk neonates. Eur. J. Pediatr.165, 422–423 (2006).
   PubMed Web of Science ®Google Scholar
• Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman B. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics109, 34–39 (2002).
   PubMed Web of Science ®Google Scholar
• Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch. Dis. Child. Fetal Neonatal Ed.91, F188–F192 (2006).
   PubMed Web of Science ®Google Scholar
• Clerihew L, Austin N, McGuire W. Systemic antifungal prophylaxis for very low birthweight infants: a systematic review. Arch. Dis. Child Fetal Neonatal Ed.93, F198–F200 (2008).
   Web of Science ®Google Scholar
• Johnsson H, Ewald U. The rate of candidaemia in preterm infants born at a gestational age of 23–28 weeks is inversely correlated to gestational age. Acta Paediatr.93, 954–958 (2004).
   PubMed Web of Science ®Google Scholar
• Makhoul IR, Bental Y, Weisbrod M et al.Candida versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J. Hosp. Infect.65, 237–243 (2007).
   PubMed Web of Science ®Google Scholar
• Hack M. Neonatology fellowship training in research pertaining to development and follow-up. J. Perinatol.26(Suppl. 2), S30–S33 (2006).
   Google Scholar
• Kramer MS, Platt RW, Wen SW et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics108, E35 (2001).
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob. Agents Chemother.50, 3496–3498 (2006).
   PubMed Web of Science ®Google Scholar
• Kaufman DA, Manzoni P, Gurka MJ, Grossman LB. Antifungal prophylaxis in the neonatal intensive care unit (NICU). Curr. Pediatr. Rev.277–288 (2007).
   Google Scholar
• White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev.11, 382–402 (1998).
   PubMed Web of Science ®Google Scholar
• Hof H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?. Drug Resist. Updat.11(1–2), 25–31 (2008).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96, 2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis.181, 309–316 (2000).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis.38, 161–189 (2004).
   PubMed Web of Science ®Google Scholar
• Sobel JD, Wiesenfeld HC, Martens M et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med.351, 876–883 (2004).
   PubMed Web of Science ®Google Scholar
• Manzoni P, Mostert M, Latino MA et al. Routinary use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr. Infect. Dis. J. (2008) (In Press).
   PubMed Web of Science ®Google Scholar
• Sarvikivi E, Lyytikainen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol.43, 2729–2735 (2005).
   PubMed Web of Science ®Google Scholar
• Yoder BA, Sutton DA, Winter V, Coalson JJ. Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr. Infect. Dis. J.23, 687–688 (2004).
   PubMed Web of Science ®Google Scholar
• Parikh TB, Nanavati RN, Patankar CV et al. Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants. Indian Pediatr.44, 830–837 (2007).
   PubMed Web of Science ®Google Scholar
• Kaufman D, Boyle R, Robinson M, Grossman LB. Long-term safety of intravenous prophylactic fluconazole use in preterm infants less than 1000 grams. [abstract]. Pediatr. Res.53, 484A (2003).
   Google Scholar
• Sims ME, Yoo Y, You H, Salminen C, Walther FJ. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am. J. Perinatol.5, 33–36 (1988).
   PubMed Web of Science ®Google Scholar
• Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses49, 484–492 (2006).
   PubMed Web of Science ®Google Scholar
• Leibovitz E, Iuster-Reicher A, Amitai M, Mogilner B. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin. Infect. Dis.14, 485–491 (1992).
   PubMed Web of Science ®Google Scholar
• Weitkamp JH, Poets CF, Sievers R et al.Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection26, 11–15 (1998).
   PubMed Web of Science ®Google Scholar
• El Masry FA, Neal TJ, Subhedar NV. Risk factors for invasive fungal infection in neonates. Acta Paediatr.91, 198–202 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson DE, Thompson TR, Green TP, Ferrieri P. Systemic candidiasis in very low-birth-weight infants (less than 1,500 grams). Pediatrics73, 138–143 (1984).
   PubMed Web of Science ®Google Scholar
• Burwell LA, Kaufman D, Blakely J, Stoll BJ, Fridkin SK. Antifungal prophylaxis to prevent neonatal candidiasis: a survey of perinatal physician practices. Pediatrics118, e1019–e1026 (2006).
   PubMed Web of Science ®Google Scholar
• Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst. Rev.CD003850 (2007).
   PubMedGoogle Scholar
• Manzoni P, Stolfi I, Pugni L et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med.356, 2483–2495 (2007).
   PubMed Web of Science ®Google Scholar
• Candidiasis. In: Red Book: 2006 Report of the Committee on Infectious Diseases. Pickering L, Baker CJ, Long SS, McMillian JA (Eds). American Academy of Pediatrics, Elk Grove Village, IL, USA 246. (2006).
   Google Scholar